# Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

Study · id `cardio:ct-nct02036970` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02036970](<https://clinicaltrials.gov/study/NCT02036970>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02036970

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.

## Technical summary

Registry record NCT02036970. Randomized; double masking; primary purpose treatment. Start 2014-05-31 (actual); primary completion 2018-01-19 (actual). Results posted on 2021-07-23.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 166 participants (enrolled count; ClinicalTrials.gov record NCT02036970, source copy `cardio:ctgov-nct02036970-2025-06-10`, retrieved 2026-10-31)
- Started: 2014-05-31 (actual) (ClinicalTrials.gov record NCT02036970, source copy `cardio:ctgov-nct02036970-2025-06-10`, retrieved 2026-10-31)
- Primary completion: 2018-01-19 (actual) (ClinicalTrials.gov record NCT02036970, source copy `cardio:ctgov-nct02036970-2025-06-10`, retrieved 2026-10-31)
- Completion: 2018-05-16 (actual) (ClinicalTrials.gov record NCT02036970, source copy `cardio:ctgov-nct02036970-2025-06-10`, retrieved 2026-10-31)
- Results first posted: 2021-07-23 (ClinicalTrials.gov record NCT02036970, source copy `cardio:ctgov-nct02036970-2025-06-10`, retrieved 2026-10-31)
- Countries: United States; Germany (ClinicalTrials.gov record NCT02036970, source copy `cardio:ctgov-nct02036970-2025-06-10`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02036970-2025-06-10`, retrieved 2026-10-31)

## The registry's words

- Brief title: Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
- Condition: Pulmonary Arterial Hypertension
- Condition: Pulmonary Hypertension
- Condition: Interstitial Lung Disease
- Condition: Idiopathic Interstitial Pneumonia
- Condition: Idiopathic Pulmonary Fibrosis
- Condition: Sarcoidosis
- Condition: Respiratory Bronchiolitis Associated Interstitial Lung Disease
- Condition: Desquamative Interstitial Pneumonia
- Condition: Cryptogenic Organizing Pneumonia
- Condition: Acute Interstitial Pneumonitis
- Condition: Idiopathic Lymphoid Interstitial Pneumonia
- Condition: Idiopathic Pleuroparenchymal Fibroelastosis
- Intervention (Drug): Bardoxolone methyl
- Intervention (Drug): Placebo
- Lead sponsor: Biogen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Biogen (`cardio:org-biogen`)

## Provenance

Content hash: 5a4c3b20db7ac6f1aac76c385a7d31ca198d19cc6461cdf14faf37b205c5764c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
